

New Technology Adoption: Considerations and Implementation Strategies

Michelle Welborn MD
Chief of Spine Surgery
Shriners Hospital for Children Portland




Disclosures

- None related to this talk
- Speaker:
 - Depuy Synthes
 - Nuvasive Spine
 - Orthopediatrics
 - Stryker Spine
 - Zimmer Spine
- Advisory board:
 - Depuy Synthes
 - Nuvasive Spine
 - Stryker Spine
 - Zimmer Biomet
 - Astrozenica
- Member:
 - SRS
 - POSNA
 - PSSG
- Grant Recipient:
 - POSNA
 - Shriners Hospital for Children
 - Zimmer Biomet



Objectives

- Delineate strategies for new technique adoption
- Identify safe risk parameters
- Identifying different educational resources for new technology adoption




First identify a problem



Shriners
Children's™
Portland

The Problem

There is an established answer but its new to you



There is no answer but you have an idea!

There is a novel technique that may be the answer

Background

Develop it:

Fund it

Execute it

Share results

Refine it

Bigger funding

Execute on a larger scale

There is a technique that is novel or new to you: Strategies for adoption

- Go to labs to learn techniques
 - Visit respected surgeons to learn
 - Critical self assessment
- Continued self assessment:
 - Review your own outcomes
 - Have others review your outcomes
 - Is your learning curve appropriate?




Shriners
Children's™
Portland

Know Thyself

- Where do you want to be on the learning curve?
What risks are you willing to take? Is it right and is it right in your hands?
 - A. Are you an alpha release kind of person (cutting edge kinda person)
 - B. A beta release (copy cat)
 - C. Go with the flow (I'll adopt it when its standard of care)
 - D. Resistant to changes (I need proof)

Technology Adoption



Shriners
Children's™
Portland

Know thy resources

- **Where do you practice?**
 - Does your institution have lots of resources
 - Are you in solo practice or a more rural setting
- **How different is it from what you are currently doing?**
 - A little different
 - A lot different




Rabbit vs Hare

So you have an idea: Innovating safely

Learn from others

- Mentors
- CHOP FDA / Surgeon Innovation Course: From Napkin Drawing to Patient Care




Be like Peter



Not all ideas are good ideas



Not all good ideas are well executed



My journey COLX- The BISS Study

- The problem- how do bones elongate?
- Identify the components of the physes
 - 1980s
- What is it's role?
 - COLX is produced in the physis during enchondral ossification
- Identify the patient problem –
 - no reliable measure for growth
 - Can CXM predict growth?
 - Is it better than what we are currently doing?

Type X collagen, a product of hypertrophic chondrocytes

Cay M. KIELTY,* Alvin P. L. KWAN,* David F. HOLMES,† Seth L. SCHOR‡ and Michael E. GRANT*§

*Department of Biochemistry and †Department of Medical Biophysics, Medical School, University of Manchester, Oxford Road, Manchester M13 9PL, and ‡Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester M20 9BX, U.K.

A Disulfide-bonded Short Chain Collagen Synthesized by Degenerative and Calcifying Zones of Bovine Growth Plate Cartilage*

(Received for publication, October 4, 1984)

William T. Grant‡, Michael D. Sussman‡§, and Gary Balian‡†

From the Departments of ‡Orthopaedics, §Pediatrics, and †Biochemistry, University of Virginia School of Medicine, Charlottesville, Virginia 22908



© 1994 Nature Publishing Group <http://www.nature.com/naturegenetics>

article

Normal long bone growth and development in type X collagen-null mice

Rita Rosati^{1,2}, Gerald S. B. Horan¹, Gerald J. Pinero³, Silvio Garofalo¹, Douglas R. Keene⁴, William A. Horton⁴, Eero Vuorio⁵, Benoit de Crombrughe¹ & Richard R. Behringer¹

Spine Deformity
<https://doi.org/10.1007/s43390-020-00262-7>

BASIC SCIENCE



Correlation of collagen X biomarker (CXM) with peak height velocity and radiographic measures of growth in idiopathic scoliosis

Michelle Cameron Welborn¹ · Ryan Coghlan¹ · Susan Sienko¹ · William Horton¹

Received: 21 January 2020 / Accepted: 21 November 2020
© Scoliosis Research Society 2021


How are we doing it?

Friends and Mentors

Research



BIOMARKER LONGITUDINAL IDIOPATHIC SCOLIOSIS STUDY



Grant funding: wait I have to pay for it?

- Small funds for pilot study to provide data to get larger funds
 - **Microgrants** -> **Young Investigator** -> **Directed Research Grant**
- Funding sources:
 - Your own institution
 - National organizations
 - AAOS, AOA, POSNA, SRS, OREF, RJOS, AOA
 - Industry grants
 - Private grants
 - Shriners grants
 - NIH:
 - loan repayment funding
 - k awards – development grants
 - R grants – research grants



How are we doing it?

Slow and Steady

Start of the BLISS Study


End of the BLISS Study



**BIOMARKER
LONGITUDINAL
IDIOPATHIC
SCOLIOSIS
STUDY**



Shriners Hospitals
for Children®



Our case:
Following patients through entire
growth curve

Background

Develop it:

Fund it

Execute
it

Share
results

Refine it


Bigger
funding

Execute on
a larger
scale

How are we doing it?

- Staying out of trouble-check/recheck
 - Reproducible results!
 - Evaluate all mediums
 - Evaluate for diurnal variation
 - Specimens assayed in quadruplicate
 - Run on multiple plates

BIOMARKER LONGITUDINAL IDIOPATHIC SCOLIOSIS STUDY



Shriners Hospitals
for Children®

Not a Flash
in the Pan



Background

Develop
it:

Fund it

Execute it

Share
results

Refine it



Bigger
funding

Execute on
a larger
scale

Stick with it



- Fail and fail again
 - Failure is the greatest key to success
- Be humble and learn from criticism
 - POSNA/ORS have whole lists of research mentors with contact info



Summary

- Know your resources and your comfort zone
- Critical self assessment
- Collaborate with people that know more than you and that you trust





Translational research
can take a lifetime but
can shape a lifetime

Thank You

 mwelborn@shrinent.org



Shriners
Children's™
Portland

